📈 🇨🇦 TSX Movers: Top Gainers & Losers (August 23rd)

In partnership with

• The TSX gained 1.5% to 28,333, bringing year-to-date gains to 14.6%, as Powell’s Jackson Hole remarks boosted markets and pushed bond yields lower.

• In Canada, the BoC has already cut rates to 2.75% but may ease further, with unemployment edging up to 6.9% and growth risks weighing on the outlook.

Big investors are buying this “unlisted” stock

When the founder who sold his last company to Zillow for $120M starts a new venture, people notice. That’s why the same VCs who backed Uber, Venmo, and eBay also invested in Pacaso.

Disrupting the real estate industry once again, Pacaso’s streamlined platform offers co-ownership of premier properties, revamping the $1.3T vacation home market.

And it works. By handing keys to 2,000+ happy homeowners, Pacaso has already made $110M+ in gross profits in their operating history.

Now, after 41% YoY gross profit growth last year alone, they recently reserved the Nasdaq ticker PCSO.

Invest for $2.90/Share

_{Paid advertisement for Pacaso’s Regulation A offering. Read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals.}

Here's a summary of the top-performing and underperforming stocks on the Toronto Stock Exchange (TSX) over the past week:

📈 Top Gainers

The Cross-Chain Giant Set for 1,000%+ Gains

As crypto markets surge, one multi-chain financial protocol is being targeted for massive institutional investment before retail discovers it.

Its transaction volume is skyrocketing across all major blockchains while its price remains suppressed as retail has yet to discover it – creating a coiled spring ready to release.

Access The $3 Report Now

📉 Top Decliners

• COSCIENS Biopharma (TSX: CSCI) reported strong Q2 2025 results with revenue up 17%, gross profit up 19%, and operating expenses down 28% year-over-year. The company restructured leadership with a new CEO and reconstituted board, cut 27% of its workforce, and announced plans to voluntarily delist from Nasdaq while retaining its TSX listing. Management is focused on streamlining operations, cost control, and optimizing its product portfolio for long-term growth.

• Burcon Nutrascience (TSX: BU) advanced its commercialization strategy in Q1 FY26 with the first commercial production and sales of Peazazz® C pea protein and the launch of FavaPro fava protein. The company signed a $6.8M multi-year production agreement, supporting revenue growth, with Q1 sales up 44% YoY to $0.34M. Its new Galesburg facility enhances scalable, flexible plant-protein production, positioning Burcon to tap into the US$215M–392M pea protein market.

Missed the Market’s Big Moves?

The market moves fast - we make sure you don’t miss a thing.

Elite Trade Club delivers clear, no-fluff market intel straight to your inbox every morning.

From stocks to big-picture trends, we cover what actually matters.

Join 100,000+ readers who start their day with the edge.

Click Here to Join Now